Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

LXRX – Lexicon Pharmaceuticals Inc.

Lexicon Pharmaceuticals, Inc.
LXRX
$1.76
Name : Lexicon Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $745,677,888.00
EPSttm : -0.14
finviz dynamic chart for LXRX
Lexicon Pharmaceuticals, Inc.
$1.76
2.92%
$0.05
LXRX — Price & Forward EBITDA
Forward EBITDA (M)

Float Short %

12.76

Margin Of Safety %

Put/Call OI Ratio

0.06

EPS Next Q Diff

-0.01

EPS Last/This Y

-0.04

EPS This/Next Y

-0.03

Price

1.72

Target Price

3.36

Analyst Recom

1.8

Performance Q

46.15

Upside

-206.4%

Beta

1.05

Ticker: LXRX




19 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-03-17LXRX1.6250.050.0537501
2026-03-18LXRX1.5650.050.0137584
2026-03-19LXRX1.6150.050.0137613
2026-03-20LXRX1.560.050.0437628
2026-03-23LXRX1.630.040.0931518
2026-03-24LXRX1.7150.040.7132534
2026-03-25LXRX1.6850.040.0132473
2026-03-26LXRX1.6250.040.0132480
2026-03-27LXRX1.6450.040.0032394
2026-03-30LXRX1.5150.042.5432706
2026-03-31LXRX1.560.060.0033505
2026-04-01LXRX1.6450.060.0334603
2026-04-02LXRX1.590.060.0034633
2026-04-06LXRX1.590.060.3334740
2026-04-07LXRX1.6050.060.0034766
2026-04-08LXRX1.6750.060.0434758
2026-04-09LXRX1.7750.060.2034668
2026-04-10LXRX1.7150.060.0034786
2026-04-13LXRX1.7150.060.0034792
DateSymbolLatestP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-03-17LXRX1.6250.0-30.5-0.18
2026-03-18LXRX1.5750.0-27.2-0.18
2026-03-19LXRX1.6250.0-32.0-0.18
2026-03-20LXRX1.5650.0-27.0-0.18
2026-03-23LXRX1.6350.0-33.0-0.18
2026-03-24LXRX1.7250.0-33.7-0.18
2026-03-25LXRX1.6850.0-28.2-0.18
2026-03-26LXRX1.6250.0-27.1-0.18
2026-03-27LXRX1.6450.0-30.2-0.18
2026-03-30LXRX1.5150.0-24.0-0.18
2026-03-31LXRX1.5650.0-32.3-0.18
2026-04-01LXRX1.6450.0-33.6-0.18
2026-04-02LXRX1.5950.0-27.5-0.18
2026-04-06LXRX1.5950.0-30.2-0.18
2026-04-07LXRX1.6150.0-30.7-0.18
2026-04-08LXRX1.6750.0-33.0-0.18
2026-04-09LXRX1.7850.0-34.7-0.18
2026-04-10LXRX1.7250.0-27.9-0.18
2026-04-13LXRX1.7250.0-29.5-0.18
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-03-17LXRX0.85-29.7012.87
2026-03-18LXRX0.85-29.7012.87
2026-03-19LXRX0.85-29.7012.87
2026-03-20LXRX0.85-29.7012.87
2026-03-23LXRX0.85-29.7012.87
2026-03-24LXRX0.85-29.7012.87
2026-03-25LXRX0.85-29.7012.62
2026-03-26LXRX0.85-29.7012.62
2026-03-27LXRX0.85-29.7012.62
2026-03-30LXRX0.85-29.7012.62
2026-03-31LXRX0.85-29.7012.62
2026-04-01LXRX0.85-29.7012.62
2026-04-02LXRX0.85-29.7012.62
2026-04-06LXRX0.85-29.7012.62
2026-04-07LXRX0.85-29.7012.62
2026-04-08LXRX0.85-29.7012.62
2026-04-09LXRX0.85-29.7012.62
2026-04-10LXRX0.85-29.7012.62
2026-04-13LXRX0.85-29.7012.76
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS

-0.04

Avg. EPS Est. Current Quarter

-0.04

Avg. EPS Est. Next Quarter

-0.06

Insider Transactions

0.85

Institutional Transactions

-29.7

Beta

1.05

Average Sales Estimate Current Quarter

9

Average Sales Estimate Next Quarter

5

Fair Value

Quality Score

45

Growth Score

36

Sentiment Score

98

Actual DrawDown %

72.9

Max Drawdown 5-Year %

-95.2

Target Price

3.36

P/E

Forward P/E

PEG

P/S

14.55

P/B

5.78

P/Free Cash Flow

EPS

-0.14

Average EPS Est. Cur. Y​

-0.18

EPS Next Y. (Est.)

-0.21

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-101.08

Relative Volume

0.28

Return on Equity vs Sector %

-74.1

Return on Equity vs Industry %

-57.6

EPS 1 7Days Diff

EPS 1 30Days Diff

0.07

EBIT Estimation

-29.5
LXRX Healthcare
$1.71
📉
Swing / Pullback
Buy the dip on strong trends
52 /100
WEAK
Trend
8/20
Pullback
14/25
Volume
11/15
Valuation
8/20
TP/AR
3/10
Options
8/10
RSI
57
Range 1M
67.1%
Sup Dist
1.9%
🚀
Momentum Growth
Ride accelerating trends
N/A
34 /100
WEAK
Momentum
9/25
Growth
10/30
Estimates
3/20
Inst/Vol
4/15
Options
8/10
EPS Yr
-26.5%
EPS NY
-16.4%
52W%
91.5%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +96.5% upside
Quality
7/30
Valuation
16/30
Growth
7/25
Stability
4/10
LT Trend
4/5
Upside
+96.5%
Quality
45
Lexicon Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 81
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors. In addition, the company develops LX9851, an orally-delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders, and pilavapadin (LX9211), an orally-delivered small molecule drug candidate for the treatment of neuropathic pain. It has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
LXRX

Latest News

Caricamento notizie per LXRX
stock quote shares LXRX – Lexicon Pharmaceuticals Inc. Stock Price stock today
news today LXRX – Lexicon Pharmaceuticals Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch LXRX – Lexicon Pharmaceuticals Inc. yahoo finance google finance
stock history LXRX – Lexicon Pharmaceuticals Inc. invest stock market
stock prices LXRX premarket after hours
ticker LXRX fair value insiders trading

LXRX – Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals, Inc.
LXRX
$1.76
Name : Lexicon Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $745,677,888.00
EPSttm : -0.14
finviz dynamic chart for LXRX
Lexicon Pharmaceuticals, Inc.
$1.76
2.92%
$0.05
LXRX — Price & Forward EBITDA
Forward EBITDA (M)

Float Short %

12.76

Margin Of Safety %

Put/Call OI Ratio

0.06

EPS Next Q Diff

-0.01

EPS Last/This Y

-0.04

EPS This/Next Y

-0.03

Price

1.72

Target Price

3.36

Analyst Recom

1.8

Performance Q

46.15

Upside

-206.4%

Beta

1.05

Ticker: LXRX




19 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-03-17LXRX1.6250.050.0537501
2026-03-18LXRX1.5650.050.0137584
2026-03-19LXRX1.6150.050.0137613
2026-03-20LXRX1.560.050.0437628
2026-03-23LXRX1.630.040.0931518
2026-03-24LXRX1.7150.040.7132534
2026-03-25LXRX1.6850.040.0132473
2026-03-26LXRX1.6250.040.0132480
2026-03-27LXRX1.6450.040.0032394
2026-03-30LXRX1.5150.042.5432706
2026-03-31LXRX1.560.060.0033505
2026-04-01LXRX1.6450.060.0334603
2026-04-02LXRX1.590.060.0034633
2026-04-06LXRX1.590.060.3334740
2026-04-07LXRX1.6050.060.0034766
2026-04-08LXRX1.6750.060.0434758
2026-04-09LXRX1.7750.060.2034668
2026-04-10LXRX1.7150.060.0034786
2026-04-13LXRX1.7150.060.0034792
DateSymbolLatestP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-03-17LXRX1.6250.0-30.5-0.18
2026-03-18LXRX1.5750.0-27.2-0.18
2026-03-19LXRX1.6250.0-32.0-0.18
2026-03-20LXRX1.5650.0-27.0-0.18
2026-03-23LXRX1.6350.0-33.0-0.18
2026-03-24LXRX1.7250.0-33.7-0.18
2026-03-25LXRX1.6850.0-28.2-0.18
2026-03-26LXRX1.6250.0-27.1-0.18
2026-03-27LXRX1.6450.0-30.2-0.18
2026-03-30LXRX1.5150.0-24.0-0.18
2026-03-31LXRX1.5650.0-32.3-0.18
2026-04-01LXRX1.6450.0-33.6-0.18
2026-04-02LXRX1.5950.0-27.5-0.18
2026-04-06LXRX1.5950.0-30.2-0.18
2026-04-07LXRX1.6150.0-30.7-0.18
2026-04-08LXRX1.6750.0-33.0-0.18
2026-04-09LXRX1.7850.0-34.7-0.18
2026-04-10LXRX1.7250.0-27.9-0.18
2026-04-13LXRX1.7250.0-29.5-0.18
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-03-17LXRX0.85-29.7012.87
2026-03-18LXRX0.85-29.7012.87
2026-03-19LXRX0.85-29.7012.87
2026-03-20LXRX0.85-29.7012.87
2026-03-23LXRX0.85-29.7012.87
2026-03-24LXRX0.85-29.7012.87
2026-03-25LXRX0.85-29.7012.62
2026-03-26LXRX0.85-29.7012.62
2026-03-27LXRX0.85-29.7012.62
2026-03-30LXRX0.85-29.7012.62
2026-03-31LXRX0.85-29.7012.62
2026-04-01LXRX0.85-29.7012.62
2026-04-02LXRX0.85-29.7012.62
2026-04-06LXRX0.85-29.7012.62
2026-04-07LXRX0.85-29.7012.62
2026-04-08LXRX0.85-29.7012.62
2026-04-09LXRX0.85-29.7012.62
2026-04-10LXRX0.85-29.7012.62
2026-04-13LXRX0.85-29.7012.76
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS

-0.04

Avg. EPS Est. Current Quarter

-0.04

Avg. EPS Est. Next Quarter

-0.06

Insider Transactions

0.85

Institutional Transactions

-29.7

Beta

1.05

Average Sales Estimate Current Quarter

9

Average Sales Estimate Next Quarter

5

Fair Value

Quality Score

45

Growth Score

36

Sentiment Score

98

Actual DrawDown %

72.9

Max Drawdown 5-Year %

-95.2

Target Price

3.36

P/E

Forward P/E

PEG

P/S

14.55

P/B

5.78

P/Free Cash Flow

EPS

-0.14

Average EPS Est. Cur. Y​

-0.18

EPS Next Y. (Est.)

-0.21

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-101.08

Relative Volume

0.28

Return on Equity vs Sector %

-74.1

Return on Equity vs Industry %

-57.6

EPS 1 7Days Diff

EPS 1 30Days Diff

0.07

EBIT Estimation

-29.5
LXRX Healthcare
$1.71
📉
Swing / Pullback
Buy the dip on strong trends
52 /100
WEAK
Trend
8/20
Pullback
14/25
Volume
11/15
Valuation
8/20
TP/AR
3/10
Options
8/10
RSI
57
Range 1M
67.1%
Sup Dist
1.9%
🚀
Momentum Growth
Ride accelerating trends
N/A
34 /100
WEAK
Momentum
9/25
Growth
10/30
Estimates
3/20
Inst/Vol
4/15
Options
8/10
EPS Yr
-26.5%
EPS NY
-16.4%
52W%
91.5%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +96.5% upside
Quality
7/30
Valuation
16/30
Growth
7/25
Stability
4/10
LT Trend
4/5
Upside
+96.5%
Quality
45
Lexicon Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 81
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors. In addition, the company develops LX9851, an orally-delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders, and pilavapadin (LX9211), an orally-delivered small molecule drug candidate for the treatment of neuropathic pain. It has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
LXRX

Latest News

Caricamento notizie per LXRX
stock quote shares LXRX – Lexicon Pharmaceuticals, Inc. Stock Price stock today
news today LXRX – Lexicon Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch LXRX – Lexicon Pharmaceuticals, Inc. yahoo finance google finance
stock history LXRX – Lexicon Pharmaceuticals, Inc. invest stock market
stock prices LXRX premarket after hours
ticker LXRX fair value insiders trading